Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Haematologica. 2018 Nov;103(11):e541-e543. doi: 10.3324/haematol.2018.194399. Epub 2018 May 24.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bendamustine Hydrochloride / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Lenalidomide / administration & dosage
  • Lymphoma, Mantle-Cell* / drug therapy
  • Lymphoma, Mantle-Cell* / genetics
  • Lymphoma, Mantle-Cell* / mortality
  • Male
  • Middle Aged
  • Mutation*
  • Rituximab / administration & dosage
  • Survival Rate
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Rituximab
  • Bendamustine Hydrochloride
  • Lenalidomide